Bulkin W, Lukashok H: Rx for dying: The case for Hospice. N Eng J Med, l988;318:376-378
2.
Fed. Register, Vol 48:243, section 418.22 and 418.26, December 16, 1983
3.
Mackillop W, O'Sullivan B, Ward G: Nonsmall cell cancer: How oncologists want to be treated. Int J Red Onc Bio Phys.1987;13:929-934
4.
Wolff SN, Herzig RH, Fay JW, et al: High dose Thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: Results of phase I and II stydies of the North American bone marrow transplantation group. J Clin Onc1989;7:245-249
5.
Love RR, Leventhal H, Easterling DV, Nerenz DR: Side Effects and emotional distress during cancer chemotherapy. Cancer1989;63:604-612
6.
Kushner R: Is aggressive adjuvant chemotherapy the Haisted radical of the ā80'sā?Ca- A Cane J for Clincl984;34;345-351
7.
Canellos GP, De Vita VT, Gold GL. et a1 Combination chemotherapy for advanced breast cancer: Response and effect on survival. Ann Intern Med1976;84;389-392
8.
Patel J, Takuma N, Vezeridis M, et al: Dose more intense palliative treatment improve over all survival in metastatic breast cancer patients?Cancerl986;57:567-570
9.
Ross M, Buzdar A, Smith T, et al: Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer1985;55:341-346
10.
Rapp E, Pater J, Willana, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer. A report of a Canadian multicenter randomized trial. J Clin Onc1988;6:633-641
11.
Einhom L, Loehrer P, Williams S, et al: Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine, cisplatin, mitomycin C in advanced nonsmall-cell lung cancer. J Clin Onc1986;4:1037-1043
12.
Buccheri GF, Ferrigno D, Curcio A, et al: Continuation of chemotherapy versus supportive care alone in patients with inoperable nonsmall cell lung cancer and stable disease after two or three cycles of MACC: Results of a randomized prospective trial. Cancer1989;63:428-432
13.
Armitage J, Cheseon B: Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Onc. 1988;6:1335-1347
14.
Vose JM, Armitage JO, Weisenburger DD, et al: The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncl988;6:1838-1844
15.
Greenberg ER, Dam B, Freeman D, Yates D, Korson R: Referral of lung cancer patients to university hospital cancer centers: A population-based study in two rural states. Cancer1988;62:1647-1652
16.
Daley J, Jencks S, Draper D, et al: Prediciting hospital-associated mortality for medicare patients: A method for patients with stroke, pneumonia, a cute myocardial infarction, and congestive heart failure. JAMA1988; 260:3125-3163
17.
Tezzoni Li, Moskowitz MA: A clinical assessment of Medisgroups. JAMA1988; 260:3159-3163
18.
Evans C, McCarthy M: Prognostic uncertainty in terminal care: Can the Karnofsky Index help?Lancetl985;1:1204-1206
19.
Forster LBLynn J: Predicting life span for applicants to impatient hospices. Arch Int Med.1988; 148:205-2543
20.
Pearlman RA: Inaccurate predictions of life expectancy: Dilemmas and opportunities (ed)Arch Int Med1988;148:2537-2538
21.
Yates JW, Chalmer B, McKegney FP: Evaluation of patients with advance cancer using the Karnofsky performance status. Cancer1980;45:220-224
22.
Reuben D, Nor V. Hiris J: Clinical symptoms and length of survival in patients with terminal cancer. Arch Int Med1988;148:1586-1591
23.
Huben RP, Murphy GP: Prostate cancer an update. CA-A Canc J for Clinic. 1986;36:274-292
24.
Tong D, Gilhick L, Hendrickson F: The palliation of symptomatic osseus metastases, final results of RTOG study. Cancer1982;50:893-899
25.
Kemeny N, Niedzwiecki D, Shurgot B.Oderman P: Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer1989;63:742-747
26.
Falkson G, Gelman R, Tormey D et al: The Eastern cooperative oncology group experience with cytoxan, adriamycin, and 5 fluorouracil (CAF) in patients with metastatic breast cancer. Cancer1985;56:219-224
27.
Tormey D, Gelman R, Band P, et al: Comparison of induction chemotherapy for metastatic breast cancer. Cancerl982;50:1235-1244
28.
Choi N, Carey R, Kaufman S et al: Small cell carcinoma of the lung: A progress report of 15 years experience. Cancer1987;59:6-14
29.
Feld R, Evans W, Coy P, et al: Canadian multicenter randomized trial comparing sequential and alternating chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Onc.1987;5:1401-1409
30.
Havenniann K, Wolf M, Holler R, et al: Alternating versus sequential chemotherapy in small cell lung cancer: A randomized German multicenter trial. Cancer1987;59:l072-1082
31.
Hirsch F, Hansen H, Hansen M, et al: The superiority of combination chemotherapy ineluding etoposide, based on in vivocell cycle analysis in in the treatment of extensive small cell lung cancer: A randomized trial of 288 consecutive patients. J Clin Onc1987;5:585-591
32.
Vuncent R, Wilson H, Lane W, et al: Progress in the chemotherapy of small cell carcinoma of the lung. Cancer1981;47:229-235
33.
Osterland K, Hansen H, Hansen M, et al: Long-term disease-free survival in small-cell carcinoma of the lung, a study of clinical determinants. I Clin Onc1986;4:l307-13l3
34.
Papac R, Son Y, Bien R, et al: Improved local control of thoracic disease in small cell lung cancer with higher dose thoraci irradiation and cyclic chemotherapy. Int J Rad Onc Bio Phy1987;13:993-998
35.
Devita V.Helhnan S, Rosenberg S (ed): Cancer, Principles and Practice of Oncology, 2nd Ed; pp 257-285. Philidelphia, J.B.Lippincott Co., 1985
36.
Kaplan LD, Abranis DI, Feigal E, et al: AIDS associated non-Hodgkin's lymphoma in San Francisco. JAMA1989;261:719-724
37.
Gills PS, Levine AM, Krailo M et al: Aids related malignant lymphoma: results of prospective treatment trials. J Clin Onc1987;5:1322-1328
38.
Klatersky J, Sculier JP, Ravez P, et al: A randomized study comparing a high and standard dose of cisplalin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Onc1986;4:1780-1786
39.
Griffin TW, Hunter RA, Cederbaum Al, et al: Treatment of advanced ovarian cancer with sequential combination chemotherapy. Cancer1987;60:2150-2155
40.
Piver S.Lele S.Marchetti D, et al: The impact of aggressive debulking surgery and cisplatun-based chemotherapy on progression free survival in stage III and IV ovarian cancer. J Clin Onc1988;6:983-989
41.
Kardinal C, Perry M, Korzun A, et al: Responses to chemotherapy or chemo-hormonal therapy in advanced breast cancer patients previously treated with adjuvant chemotherapy. Cancer1988;61:415-419
42.
Maurer L, Tulloh M, Weiss R, et al: A randomized combined modality trial in small cell carcinoma of the lung. Cancer1980;45:30-39
43.
Millstein D, Robinson E: Four-drug combination chemotherapy in advanced lung cancer: Methotrexate, doxorubicin, cyclophosphamide, and CCNU.Cancer1981;48:2358-2363
44.
Shepard K, Golomb H, Bitran J, et al: CAMP chemotherapy for metastatic no-oat cell bronchogenic carcinoma. Cancer1985;56:2385-2390
45.
Rodriquez-Kraul R, Hortobagyi G, Buzdar A, Blumenschein G: Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer1981;48:227-232
46.
Jones R, Holland J, Bhardwaj S, et al: A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Onc1987;5:172-177
47.
Romond E, Metcalfe M, MacDonald J: Palliative chemotherapy and hormonal therapy. Sem One. 1985;12:384-389
48.
Sorensen J, Hansen H, Dombernowsky P, et al. Chemotherapy for adenocasrcinoma of the lung (WHO III): A randomized study of viadesine versus lomustine, cyclophoasphamide, and methotrexate versus all four drugs. J Clin Onc1987;5:1169-1177
49.
Popert K, Anderson J: Assessing the effect of toxicity on prognosis: Methods of analysis and interpretation. J Clin Onc1988;6:868-870
50.
Bonadonna G, Valgussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N. Eng J Med1981;304:10-15
51.
Hryniuk W, Levine M: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Onc. 1986;4:1162-1170
52.
Ahmann D, Sehaid D, Bisel H, Hahn R, et al: The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. J Clin Onc1987;5:1928-1932
53.
Carbone P: High-dose chemotherapy for breast cancer (ed)J Clin Onc1987;5:167-168
54.
Rosner D, Nemoto T, Lane W: A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer. Cancer1987;59:874-883
55.
Jones R, Holland J, Bhardwaj S, et al: A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Onc1987;5:172-177
56.
Tannoek I, Boyd N, Deboer G, et al: A randomized trial of low dose levels of cytoxan, methotrexate, a 5-fluorouracil chemotherapy for patients with metastatic breast cancinoma. Cancer1988;6:1377-1387
57.
Hum S, Pazdur R, Singhakowinta A, et al: Low-dose continuous infusion 5-fluorouracil: Evaluation in advanced breast carcinoma. Cancer1989;63:419-422
58.
Valagussa P.Taneini G, Bonadonna G: Salvage treatment of patients suffering relapse after adjuv ant CMF chemotherapy. Cancer1986;58:1411-1417
59.
Rapp E, Peter J, Willana, et al: Chemotherapy can prolong survival in patients in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Onc. 1988;6:633-641
60.
Thatcher N, Cerny T, Stout R, et al: Ifos-famide, etoposide, and thoraeie irradiation in 163 patients with unreseetable small cell lung carcinoma. Cancer1987;60:2382-2387
61.
York RM, Foltz A: Bleomycin, vineristine, lomustine, and DTIC chemotherapy for metastatie melanoma. Cancer1988;61:2183-2183
62.
Kies M, Mira J, Crowley J, et al: Multirnodal therapy for limited small-cell lung cancer. Arndomized study of induction combination chemotherapy with or without thoraci radiation in complete responders; and with wide-field versus reduced files radiation in partial responders: A Southwest Oncology Group Study. J Clin Onc1987;5:592-600
63.
Aaronson NK: Quality of life: What is it? How should it be measured?Oncology1988;2:69-7651
64.
Fettung JH: Evaluating quality and quantity of life in breast cancer adjuvanttrials (ed). J Clin Onc1988;6:1795-1797
65.
Schipper H, Levitt M: Measuring quality of life, risks and benefits. Cane Treat Rpts1985;69:1115-1123
66.
Spitzer W, Dobson A, Hall J, et al: Measuring the quality of life of cancer patients. J Chron Dis1981;34:585-597
67.
Bartelink H, Van Dam F, Van Dongen J: Psychological effects of breast conserving therapy in comparison with radical mastectomy. Int J Rad Onc Bio Phys1985;11:381-385
68.
Evans R, Mannine D, Garrison L, et al: Quality of life of patients with end-stage renal disease. N Eng J Med1985;312:553-559
69.
Vera M: Quality of life following pelvic exenteration. Gyn One1981;12:355-366
70.
Lanham R, DiGiannantonio A: Quality of life of Cancer Patients. Oncology1988;(45)1-7
71.
McNeil B, Weichselbaum R, Pauker S: Speech and survival tradeoffs between quality and quantity of life in laryngeal cancer. N Eng J Med1981;305:982-987
72.
Priestman T, Baum M: Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet1976;1:899-900
73.
Gelber R, Goldhirsch A: A new endpoint for the assesment of adjuvant therapy in postmenopausal women with operable breast cancer, J Clin Onc1986;4:1772-1779
74.
Goodwin PJ, Feld R, Evans WK, Pater J: Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. Journal of Clin Onc1988;6:1537-1547
75.
Levine MN, Guyatt GH, Gent M, et al: Quality of life in stage II breast cancer: An instrument for clinical trials. J Clin Onc1988;6:1789-1810
76.
Goldhirsch A, Gelber RD, Simes RJ, et al: Costs and benefits of adjuvanttherapy in breast cancer: A quality-adjusted survival analysis. J Clin Onc. 1989;7:36-44
